<DOC>
	<DOC>NCT00289809</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined with ifosfamide and then the efficacy of this combination in terms of overall response rate, time to progression and time of response</brief_summary>
	<brief_title>TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients</brief_title>
	<detailed_description>The Maximum Tolerated Dose of the combination was determined and the Phase I terminated. Then, Phase II study started.</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologic diagnosis of soft tissue sarcoma metastatic or recurrent after 6 months from the last chemotherapy Age &gt;/=18 yrs PS &lt;/=2 Disease detectable almost for 1 dimension Life expectancy &gt;/=3 mos Minimum 4 wks from last radiotherapy Adequate medullary, liver, and renal functions Normal LVEF Written Informed Consent Pregnant or breastfeeding patients Serious concomitant disease or not controlled infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>